Current Trends and Healthcare Resource Usage in the Hospital Treatment of Primary Malignant Brain Tumor in Japan: A National Survey Using the Diagnostic Procedure Combination Database (J-ASPECT Study-Brain Tumor).
We conducted this study to clarify the current trends and healthcare resource usage in the treatment of inpatients with primary malignant brain tumors. The Diagnostic Procedure Combination (DPC) data of all inpatients treated between 2013 and 2014 in the 370 core and branch hospitals enrolled in the Japanese Neurosurgical Society training program were collected. DPC is a discharge abstract and administrative claims database of inpatients. We assessed 6,142 primary, malignant brain tumor patients. Patient information, diagnostic information, treatment procedure, and healthcare resource usage were analyzed. Chemotherapy was the most frequent treatment (27% of cases), followed by surgery (13%) and surgery + chemo-radiotherapy (11%). Temozolomide (TMZ), the most frequently used chemotherapeutic drug, was administered to 1,236 patients. Concomitant TMZ and radiotherapy was administered to 816 patients, and was performed according to the Stupp regimen in many cases. The mean length of hospital stay (LOS) was 16 days, and the mean medical cost was 1,077,690 yen. The average medical cost of TMZ-only treatment was 1,138,620 yen whilst it was 4,424,300 yen in concomitant TMZ patients. The LOS was significantly shorter in high-volume than in low-volume hospitals, and the medical cost was higher in hospitals treating 21-50 patients compared to those treating 1-10 patients. However, the direct medical cost of TMZ treatment was the same across different volume hospitals. This is the first report of current trends and healthcare resource usage in the treatment of primary malignant brain tumor inpatients in the TMZ era in Japan.
Department of Neurosurgery, Graduate School of Medical Sciences, Kyushu University.
Koji
K
Yoshimoto
Akiko
A
Kada
Daisuke
D
Kuga
Ryusuke
R
Hatae
Hideki
H
Murata
Yojiro
Y
Akagi
Kunihiro
K
Nishimura
Ryota
R
Kurogi
Ataru
A
Nishimura
Nobuhiro
N
Hata
Masahiro
M
Mizoguchi
Tetsuro
T
Sayama
Koji
K
Iihara
D000293:Adolescent; D000328:Adult; D000368:Aged; D001932:Brain Neoplasms / Q000175:diagnosis / Q000453:epidemiology / Q000628:therapy*; D002648:Child; D019992:Databases as Topic; D005260:Female; D017048:Health Care Costs / Q000706:statistics & numerical data; D006295:Health Resources / Q000706:statistics & numerical data*; D006760:Hospitalization / Q000706:statistics & numerical data*; D006801:Humans; D007564:Japan / Q000453:epidemiology; D008297:Male; D008875:Middle Aged; D011795:Surveys and Questionnaires; D055815:Young Adult
J Stroke Cerebrovasc Dis. 2014 May-Jun;23(5):1001-18
24103675
Lancet Oncol. 2009 May;10 (5):459-66
19269895
Cancer. 2004 Nov 1;101(9):2098-105
15389472
J Oncol Pract. 2015 Jan;11(1):e59-65
25466707
PLoS One. 2014 May 14;9(5):e96819
24828409
J Am Heart Assoc. 2014 Oct 21;3(5):e001059
25336463
Neuro Oncol. 2002 Oct;4(4):278-99
12356358
Am Health Drug Benefits. 2014 May;7(3):140-9
24991398
Int J Clin Oncol. 2011 Aug;16(4):314-21
21240684
N Engl J Med. 2015 Nov 5;373(19):1793-7
26535509
Neuro Oncol. 2011 Oct;13(10):1049-58
21784756
Health Policy. 2012 Oct;107(2-3):194-201
22277879
Neuro Oncol. 2014 Oct;16 Suppl 4:iv1-63
25304271
Cancer. 2008 Mar 15;112(6):1337-44
18213621
Neuro Oncol. 2013 Nov;15(11):1532-42
23935155